DE69406649D1 - N-alkyl-2-substituierte atp-analoge - Google Patents

N-alkyl-2-substituierte atp-analoge

Info

Publication number
DE69406649D1
DE69406649D1 DE69406649T DE69406649T DE69406649D1 DE 69406649 D1 DE69406649 D1 DE 69406649D1 DE 69406649 T DE69406649 T DE 69406649T DE 69406649 T DE69406649 T DE 69406649T DE 69406649 D1 DE69406649 D1 DE 69406649D1
Authority
DE
Germany
Prior art keywords
alkyl
independently represent
atp analogs
halogen
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69406649T
Other languages
English (en)
Other versions
DE69406649T2 (de
Inventor
Anthony Howard Ingall
Peter Alan Cage
Nicholas David Kindon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astra Pharmaceuticals Ltd
Astra USA Inc
Original Assignee
Astra Pharmaceuticals Ltd
Astra Pharmaceutical Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939302636A external-priority patent/GB9302636D0/en
Priority claimed from GB939325712A external-priority patent/GB9325712D0/en
Application filed by Astra Pharmaceuticals Ltd, Astra Pharmaceutical Products Inc filed Critical Astra Pharmaceuticals Ltd
Publication of DE69406649D1 publication Critical patent/DE69406649D1/de
Application granted granted Critical
Publication of DE69406649T2 publication Critical patent/DE69406649T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
DE69406649T 1993-02-10 1994-02-08 N-alkyl-2-substituierte atp-analoge Expired - Lifetime DE69406649T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939302636A GB9302636D0 (en) 1993-02-10 1993-02-10 Compounds
GB939325712A GB9325712D0 (en) 1993-12-16 1993-12-16 Compounds
PCT/GB1994/000237 WO1994018216A1 (en) 1993-02-10 1994-02-08 N-alkyl-2-substituted atp analogues

Publications (2)

Publication Number Publication Date
DE69406649D1 true DE69406649D1 (de) 1997-12-11
DE69406649T2 DE69406649T2 (de) 1998-03-05

Family

ID=26302434

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69406649T Expired - Lifetime DE69406649T2 (de) 1993-02-10 1994-02-08 N-alkyl-2-substituierte atp-analoge

Country Status (26)

Country Link
US (2) US5721219A (de)
EP (1) EP0683789B1 (de)
JP (1) JP3083156B2 (de)
KR (1) KR100315612B1 (de)
CN (1) CN1042430C (de)
AT (1) ATE159950T1 (de)
AU (1) AU679721B2 (de)
CA (1) CA2155673C (de)
CZ (1) CZ286050B6 (de)
DE (1) DE69406649T2 (de)
DK (1) DK0683789T3 (de)
ES (1) ES2108425T3 (de)
FI (1) FI110687B (de)
GR (1) GR3025995T3 (de)
HK (1) HK1002936A1 (de)
HU (1) HU221501B (de)
IL (1) IL108602A (de)
NO (1) NO305209B1 (de)
NZ (1) NZ261159A (de)
PL (1) PL175623B1 (de)
RU (1) RU2136693C1 (de)
SG (1) SG47943A1 (de)
SK (1) SK281309B6 (de)
TW (1) TW326045B (de)
UA (1) UA54366C2 (de)
WO (1) WO1994018216A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2108425T3 (es) * 1993-02-10 1997-12-16 Astra Pharma Prod Analogos de atp sustituidos con n-alquilo-2.
CA2241687A1 (en) * 1996-10-30 1998-05-07 Kenneth A. Jacobson P2y receptor antagonists
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
AU2003257524B2 (en) * 1997-07-11 2006-04-06 Astrazeneca Ab New formulation
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
FI104901B (fi) * 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
US6750340B2 (en) * 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en) 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6303774B1 (en) * 1999-08-20 2001-10-16 Sri International Nucleoside pyrophosphate and triphosphate analogs and related compounds
SE9903345D0 (sv) 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
AR039558A1 (es) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7018985B1 (en) * 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
CA2477741A1 (en) * 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
IL166312A0 (en) * 2002-07-18 2006-01-15 Sankyo Co A pharmaceutical composition containing an adp receptor antagonist and an acat inhibitor
US20050192245A1 (en) * 2002-07-18 2005-09-01 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
EP1563858A4 (de) * 2002-11-21 2010-09-29 Kowa Co Verfahren für die peritonealdialyse
US8293890B2 (en) * 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
EP1604669A1 (de) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von ATP-Analogen zur Behandlung von kardiovaskulären Erkrankungen
US20130303477A1 (en) * 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) * 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EA028885B1 (ru) * 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)
US9493502B2 (en) 2011-01-26 2016-11-15 Beijing Kbd Pharmaceuticals Co., Ltd. Ribofuranosyl purine compounds, methods for preparing the same and use thereof
JP5947316B2 (ja) 2011-02-09 2016-07-06 ザ メディシンズ カンパニー 肺高血圧症を処置するための方法
WO2013019874A1 (en) 2011-08-01 2013-02-07 Mbc Pharma, Inc. Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
EP2964233B1 (de) 2013-03-09 2021-12-15 Chiesi Farmaceutici S.p.A. Verfahren zur behandlung, verringerung der inzidenz und/oder prävention von ischämischen ereignissen
CN104447928A (zh) * 2013-09-13 2015-03-25 天津市汉康医药生物技术有限公司 坎格雷洛二水化合物
CN104447927A (zh) * 2013-09-13 2015-03-25 天津市汉康医药生物技术有限公司 坎格雷洛一水合物晶体及其制备方法
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN105273025B (zh) * 2014-07-22 2019-07-26 上海医药工业研究院 一种制备坎格雷洛的中间体及其制备方法和应用
BR112017014996A2 (pt) 2015-01-14 2018-03-20 Chiesi Farm Spa formulações farmacêuticas e recipientes selados
CN105061431B (zh) * 2015-07-28 2017-03-29 山东百诺医药股份有限公司 6‑n‑（2‑（甲硫基）乙基）‑2‑（（3,3,3‑三氟丙基）硫代）‑9h‑嘌呤及其制备方法和应用
WO2017076266A1 (zh) * 2015-11-06 2017-05-11 江苏恒瑞医药股份有限公司 制备坎格雷洛中间体的方法
CN107973798B (zh) * 2016-10-25 2020-04-24 上海医药工业研究院 2-[(3,3,3-三氟丙基)硫代]-6-氨基-9h-嘌呤及制法
CN107973832B (zh) * 2016-10-25 2021-11-12 上海医药工业研究院 6-n-[2-(甲硫基)乙基]-2-[(3，3，3-三氟丙基)硫代]腺苷的制法
CN106674322B (zh) * 2016-12-07 2019-04-16 上海博志研新药物技术有限公司 一种坎格雷洛中间体的纯化方法
WO2018185715A1 (en) * 2017-04-06 2018-10-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of n6-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with (dichloromethylene) bisphosphonic acid and its pharmaceutically acceptable salts
BR112019022676A2 (pt) 2017-06-23 2020-05-19 Chiesi Farm Spa método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar
ES2905104T3 (es) * 2017-11-10 2022-04-07 Olon Spa Método eficiente para la preparación de Cangrelor
CN109912674A (zh) * 2017-12-12 2019-06-21 亚宝药业集团股份有限公司 一种坎格雷洛四钠盐的制备方法
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
US20190241606A1 (en) * 2018-02-05 2019-08-08 Scinopharm Taiwan, Ltd. Process for preparation of cangrelor tetrasodium and intermediate therefor
CN108033983B (zh) * 2018-02-09 2021-06-08 盐城锦明药业有限公司 一种2‐(3,3,3‐三氟丙基)硫代腺苷的合成方法
EP4289435A1 (de) 2022-06-07 2023-12-13 Université de Liège N-alkyl-2-substituierten atp-analogen zur verwendung als antibacterieller wirkstoff

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049550A (en) * 1987-11-05 1991-09-17 Worcester Foundation For Experimental Biology Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents
EP0464206A4 (en) * 1989-03-24 1992-05-13 Daiichi Pharmaceutical Co., Ltd. Drug for improving brain function
GB9107236D0 (en) 1991-04-06 1991-05-22 Fisons Plc Compounds
ES2078654T3 (es) * 1991-04-06 1995-12-16 Astra Pharma Prod Analogos de atp.
ES2108425T3 (es) * 1993-02-10 1997-12-16 Astra Pharma Prod Analogos de atp sustituidos con n-alquilo-2.

Also Published As

Publication number Publication date
CA2155673C (en) 2004-08-17
IL108602A0 (en) 1994-05-30
WO1994018216A1 (en) 1994-08-18
ES2108425T3 (es) 1997-12-16
ATE159950T1 (de) 1997-11-15
HU221501B (en) 2002-10-28
US5955447A (en) 1999-09-21
FI953794A0 (fi) 1995-08-10
JP3083156B2 (ja) 2000-09-04
NO953126D0 (no) 1995-08-09
NZ261159A (en) 1997-06-24
FI110687B (fi) 2003-03-14
SK281309B6 (sk) 2001-02-12
AU5977094A (en) 1994-08-29
RU2136693C1 (ru) 1999-09-10
PL310160A1 (en) 1995-11-27
CZ286050B6 (cs) 1999-12-15
TW326045B (en) 1998-02-01
JPH08506335A (ja) 1996-07-09
CN1119869A (zh) 1996-04-03
SK99495A3 (en) 1996-02-07
CN1042430C (zh) 1999-03-10
NO953126L (no) 1995-09-28
GR3025995T3 (en) 1998-04-30
CZ203295A3 (en) 1995-12-13
AU679721B2 (en) 1997-07-10
DK0683789T3 (da) 1998-02-09
DE69406649T2 (de) 1998-03-05
HUT72464A (en) 1996-04-29
EP0683789B1 (de) 1997-11-05
FI953794A (fi) 1995-08-10
CA2155673A1 (en) 1994-08-18
NO305209B1 (no) 1999-04-19
PL175623B1 (pl) 1999-01-29
US5721219A (en) 1998-02-24
HK1002936A1 (en) 1998-09-25
EP0683789A1 (de) 1995-11-29
UA54366C2 (uk) 2003-03-17
SG47943A1 (en) 1998-04-17
KR100315612B1 (ko) 2002-06-20
IL108602A (en) 1999-12-22

Similar Documents

Publication Publication Date Title
DE69406649D1 (de) N-alkyl-2-substituierte atp-analoge
CY1106166T1 (el) Παραγωγα κουιναζολινης ως αναστολεις vegf.
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
HUP0104058A2 (hu) N-diszubsztituált piperazin vagy 1,4 diszubsztituált piperidin heterociklusos származékai és ezeket tartalmazó gyógyászati készítmények
ES467069A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1-3-bencenodimetanol
HUP0202379A2 (hu) Új vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0204217A2 (en) Novel a-500359 derivatives
AU639154B2 (en) New imidazole compounds, a process for the preparation thereof, and pharmaceutical compositions containing them
HUP0100751A2 (hu) Új aril-vagy heteroaril-kinolinilfoszfonsav-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyszerkészítmények
ES2163104T3 (es) Pseudopeptidos derivados de neuroquininas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition